PRLD - Prelude Therapeutics GAAP EPS of -$0.63 beats by $0.02 May, 10 2022 08:57 AM Prelude Therapeutics Incorporated Prelude Therapeutics press release (NASDAQ:PRLD): Q1 GAAP EPS of -$0.63 beats by $0.02. Cash and cash equivalents of $266.2M For further details see: Prelude Therapeutics GAAP EPS of -$0.63 beats by $0.02